Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Merck
Fish and Richardson
Moodys
Accenture
McKinsey
McKesson
Covington
Cantor Fitzgerald

Generated: April 23, 2018

DrugPatentWatch Database Preview

LAMISIL AT Drug Profile

« Back to Dashboard

Which patents cover Lamisil At, and when can generic versions of Lamisil At launch?

Lamisil At is a drug marketed by Glaxosmithkline Cons and is included in two NDAs.

The generic ingredient in LAMISIL AT is terbinafine hydrochloride. There are twenty-seven drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the terbinafine hydrochloride profile page.
Drug patent expirations by year for LAMISIL AT
Synonyms for LAMISIL AT
(([(2E)-6,6-DIMETHYLHEPT-2-EN-4-YN-1-YL](METHYL)AMINO)METHYL)NAPHTHALENE HYDROCHLORIDE
(2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine hydrochloride
(2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-aminium chloride
(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride
(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine monohydrochloride
(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine hydrochloride
(E)-N-(6,6-DIMETHYL-2-HEPTEN-4-YNYL)-N-METHYL-1-NAPHTHYLMETHYLAMINE HYDROCHLORIDE
(E)-N-(6,6-DIMETHYL-HEPT-2-EN-4-YNYL)-N-METHYL-N-(NAPHTHALENE-1-YLMETHYL)-AMINE HYDROCHLORIDE
(E)-N,6,6-trimethyl-N-(1-naphthalenylmethyl)-1-hept-2-en-4-ynamine hydrochloride
(E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine hydrochloride
(E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine hydrochloride
(E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine;hydrochloride
012C11ZU6G
1-Naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)-, monohydrochloride
1-Naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)-,monohydrochloride
628T805
78628-80-5
A1-01779
A839463
AB0013345
AB03963
AB2000653
AC-761
AC1NR04Y
Afogan
AK161974
AKOS015844100
AKOS025149216
AN-6967
API0004353
Athletes foot
B2047
BB_SC-1130
BC220359
BCP9000834
BWMISRWJRUSYEX-SZKNIZGXSA-N
C-19912
C21H25N.HCl
C21H26ClN
CCG-101026
CHEBI:77614
CHEMBL1200832
CPD000469152
CS-1123
CT0259
D02219
D2049
DRG-0286
DTXSID90229223
H901
HTU-520
HY-17395
I06-0127
I06-127
I14-0662
InnoNyx
J10383
KB-60713
KS-1289
Lamisil
Lamisil (TN)
Lamisil Krem
LS-94723
MFCD00145430
MLS001066620
MLS001304037
MLS001401424
MolPort-001-758-011
mycoCeaze
MycoVa
N-[(2E)-6,6-DIMETHYL-2-HEPTEN-4-YN-1-YL]-N-METHYL-1-NAPHTHALENEMETHANAMINE, MONOHYDROCHLORIDE
N-[(2E)-6,6-DIMETHYL-2-HEPTEN-4-YNYL]-N-METHYL-1-NAPHTHALENEMETHANAMINE HYDROCHLORIDE
N,6,6-TRIMETHYL-N-(NAPHTHALEN-1-YLMETHYL)HEPT-2-EN-4-YN-1-AMINE HYDROCHLORIDE
NC00276
NM-100060
NSC-759113
NSC759113
Pharmakon1600-01505392
Q-201790
s2557
SAM001246565
SBB066075
SC-14146
SCHEMBL36793
SCHEMBL36795
SDZ SF 86-327
Sebifin
SF 86-327 hydrochloride
SF-86327
SMR000469152
ST24049333
TerbiFoam
Terbinafina
Terbinafina [Spanish]
Terbinafine (hydrochloride)
Terbinafine for system suitability, European Pharmacopoeia (EP) Reference Standard
Terbinafine HCl
Terbinafine HCl (Lamisil)
Terbinafine hydrochioride
Terbinafine hydrochloride
Terbinafine hydrochloride (JP17/USP)
Terbinafine hydrochloride (Lamisil)
Terbinafine hydrochloride [USP:JAN]
Terbinafine hydrochloride, >=98%
Terbinafine hydrochloride, Antibiotic for Culture Media Use Only
Terbinafine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Terbinafine hydrochloride, pharmaceutical secondary standard; traceable to USP and PhEur
Terbinafine hydrochloride, United States Pharmacopeia (USP) Reference Standard
terbinafine monohydrochloride
Terbinafine,hydrochloride
Terbinafinum
Terbinafinum [Latin]
Terbisil
TR-025130
TRANS-N-(6,6-DIMETHYL-2-HEPTEN-4-YLYL)-N-METHYL-1-NAPHTHYLMETHYLAMINE HYDROCHLORIDE
trans-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthylmethylamine Hydrochloride
Trebinafine hydrochloride
UNII-012C11ZU6G
W-5081
Zabel
Zimig

US Patents and Regulatory Information for LAMISIL AT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SOLUTION;TOPICAL 021124-001 Mar 17, 2000 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SPRAY;TOPICAL 021124-002 Mar 17, 2000 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for LAMISIL AT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SPRAY;TOPICAL 021124-002 Mar 17, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SOLUTION;TOPICAL 021124-001 Mar 17, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SOLUTION;TOPICAL 021124-001 Mar 17, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Colorcon
AstraZeneca
US Army
Deloitte
Baxter
Mallinckrodt
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.